In Brief: Rhone-Poulenc Rorer's Nasacort AQ

27 May 1996
News

The Pink Sheet pinkeditor@informa.com

Executive Summary

Rhone-Poulenc Rorer's Nasacort AQ: Water-based formulation of Nasacort for treatment of allergic rhinitis will be available in the end of June following May 20 FDA clearance, company announces. The CFC propellant-free aqueous microcrystalline suspension is indicated for once-daily use in children over age 12 and adults. Also, Nasacort was approved in children over age six, recommended at the same starting dose of 220 mcg per day given as two sprays in each nostril...

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS028221

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS028221

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

In Brief: Rhone-Poulenc Rorer's Nasacort AQ

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert